drugset / Trial / NCT00939731
Relative Drug Exposures Of Two Formulations of PF-02341066
RandomizedCrossoverOpen-labelBasic science
Summary
The study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over, single-dose study employing administration of two PF-02341066 formulations in the fasted state to healthy adult volunteers.
Timeline
- Start
- 2009-07
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crizotinib | Small molecule | 250 mg | — |
Indications
No indication recorded.